Mismatch between circulating cytokines and spontaneous cytokine production by leukocytes in hyperinflammatory COVID-19.


Journal

Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628

Informations de publication

Date de publication:
01 2021
Historique:
received: 19 05 2020
revised: 15 07 2020
accepted: 17 07 2020
pubmed: 15 8 2020
medline: 2 3 2021
entrez: 15 8 2020
Statut: ppublish

Résumé

The disease COVID-19 has developed into a worldwide pandemic. Hyperinflammation and high levels of several cytokines, for example, IL-6, are observed in severe COVID-19 cases. However, little is known about the cellular origin of these cytokines. Here, we investigated whether circulating leukocytes from patients with COVID-19 had spontaneous cytokine production. Patients with hyperinflammatory COVID-19 (n = 6) and sepsis (n = 3) were included at Skåne University Hospital, Sweden. Healthy controls were also recruited (n = 5). Cytokines were measured in COVID-19 and sepsis patients using an Immulite immunoassay system. PBMCs were cultured with brefeldin A to allow cytokine accumulation. In parallel, LPS was used as an activator. Cells were analyzed for cytokines and surface markers by flow cytometry. High levels of IL-6 and measurable levels of IL-8 and TNF, but not IL-1β, were observed in COVID-19 patients. Monocytes from COVID-19 patients had spontaneous production of IL-1β and IL-8 (P = 0.0043), but not of TNF and IL-6, compared to controls. No spontaneous cytokine production was seen in lymphocytes from either patients or controls. Activation with LPS resulted in massive cytokine production by monocytes from COVID-19 patients and healthy controls, but not from sepsis patients. Finally, monocytes from COVID-19 patients produced more IL-1β than from healthy controls (P = 0.0087) when activated. In conclusion, monocytes contribute partly to the ongoing hyperinflammation by production of IL-1β and IL-8. Additionally, they are responsive to further activation. This data supports the notion of IL-1β blockade in treatment of COVID-19. However, the source of the high levels of IL-6 remains to be determined.

Identifiants

pubmed: 32794348
doi: 10.1002/JLB.5COVBCR0720-310RR
pmc: PMC7436862
doi:

Substances chimiques

Cytokines 0

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115-120

Informations de copyright

© 2020 The Authors. Journal of Leukocyte Biology published by Wiley Periodicals LLC on behalf of Society for Leukocyte Biology.

Références

Shock. 2012 Dec;38(6):577-83
pubmed: 23143060
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Crit Care. 2013 Nov 14;17(6):242
pubmed: 24229432
Emerg Microbes Infect. 2020 Dec;9(1):761-770
pubmed: 32228226
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
N Engl J Med. 2013 Aug 29;369(9):840-51
pubmed: 23984731
J Immunol. 2011 Jun 15;186(12):7243-54
pubmed: 21576504
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
EBioMedicine. 2015 Apr 1;2(4):324-333
pubmed: 26029736
Immunity. 2015 Mar 17;42(3):484-98
pubmed: 25746953
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Crit Care Med. 2019 Apr;47(4):508-516
pubmed: 30585832
Am J Respir Crit Care Med. 2012 Nov 1;186(9):838-45
pubmed: 22822024
Nat Med. 1997 Jun;3(6):678-81
pubmed: 9176497
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14978-83
pubmed: 19706447
Lancet Infect Dis. 2013 Mar;13(3):260-8
pubmed: 23427891
Intensive Care Med. 2006 Aug;32(8):1175-83
pubmed: 16741700
Toxicol Res. 2018 Jan;34(1):65-73
pubmed: 29372003
Crit Care Med. 2009 Apr;37(4):1261-7
pubmed: 19242351
J Biol Chem. 2018 Nov 9;293(45):17631-17645
pubmed: 30242126
J Biol Chem. 2013 Feb 8;288(6):3897-906
pubmed: 23264622
J Innate Immun. 2016;8(1):97-107
pubmed: 26228026
J Leukoc Biol. 2019 Jul;106(1):11-25
pubmed: 31169935
J Leukoc Biol. 2019 Jul;106(1):7-9
pubmed: 31087702
Front Immunol. 2018 Nov 19;9:2685
pubmed: 30510555
J Lab Clin Med. 2000 Feb;135(2):153-60
pubmed: 10695660
Trends Immunol. 2009 Oct;30(10):475-87
pubmed: 19781994
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
J Leukoc Biol. 2011 Dec;90(6):1141-8
pubmed: 21934070
Nat Immunol. 2016 Apr;17(4):406-13
pubmed: 26950237
Natl Sci Rev. 2020 Jun;7(6):998-1002
pubmed: 34676125
J Leukoc Biol. 2017 Jan;101(1):151-164
pubmed: 27272310

Auteurs

Robin Kahn (R)

Department of Clinical Sciences Lund, Section of Pediatrics, Lund University, Lund, Sweden.
Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.
Skåne University Hospital, Lund and Malmö, Sweden.

Tobias Schmidt (T)

Department of Clinical Sciences Lund, Section of Pediatrics, Lund University, Lund, Sweden.
Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.

Karan Golestani (K)

Skåne University Hospital, Lund and Malmö, Sweden.

Anki Mossberg (A)

Department of Clinical Sciences Lund, Section of Pediatrics, Lund University, Lund, Sweden.
Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.

Birgitta Gullstrand (B)

Department of Clinical Sciences Lund, Rheumatology Lund University, Lund, Sweden.

Anders A Bengtsson (AA)

Department of Clinical Sciences Lund, Rheumatology Lund University, Lund, Sweden.

Fredrik Kahn (F)

Skåne University Hospital, Lund and Malmö, Sweden.
Department of Clinical Sciences Lund, Section of Infection Medicine, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH